Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Jun;15(3):152-9.
doi: 10.1136/tc.2005.011551.

Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison

J Cornuz  1 , A Gilbert, C Pinget, P McDonald, K Slama, E Salto, F Paccaud
Affiliations
Comparative Study

Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison

J Cornuz et al. Tob Control. 2006 Jun.

Abstract

Objective: To estimate the incremental cost-effectiveness of the first-line pharmacotherapies (nicotine gum, patch, spray, inhaler, and bupropion) for smoking cessation across six Western countries-Canada, France, Spain, Switzerland, the United States, and the United Kingdom.

Design and study population: A Markov-chain cohort model to simulate two cohorts of smokers: (1) a reference cohort given brief cessation counselling by a general practitioner (GP); (2) a treatment cohort given counselling plus pharmacotherapy. Effectiveness expressed as odds ratios for quitting associated with pharmacotherapies. Costs based on the additional physician time required and retail prices of the medications.

Interventions: Addition of each first-line pharmacotherapy to GP cessation counselling.

Main outcome measures: Cost per life-year saved associated with pharmacotherapies.

Results: The cost per life-year saved for counselling only ranged from US190 dollars in Spain to 773 dollars in the UK for men, and from 288 dollars in Spain to 1168 dollars in the UK for women. The incremental cost per life-year saved for gum ranged from 2230 dollars for men in Spain to 7643 dollars for women in the US; for patch from 1758 dollars for men in Spain to 5131 dollars for women in the UK; for spray from 1935 dollars for men in Spain to 7969 dollars for women in the US; for inhaler from 3480 dollars for men in Switzerland to 8700 dollars for women in France; and for bupropion from 792 dollars for men in Canada to 2922 dollars for women in the US. In sensitivity analysis, changes in discount rate, treatment effectiveness, and natural quit rate had the strongest influences on cost-effectiveness.

Conclusions: The cost-effectiveness of the pharmacotherapies varied significantly across the six study countries, however, in each case, the results would be considered favourable as compared to other common preventive pharmacotherapies.

PubMed Disclaimer

Conflict of interest statement

Competing interest: none to declare

References

    1. Peto R, Lopez A D, Boreham J.et alMortality from smoking in developed countries, 1950–2000. Oxford, UK: Oxford University Press, 1994
    1. Jha P, Chaloupka F J.Curbing the epidemic: governments and the economics of tobacco control. Washington DC: World Bank, 1999
    1. Doll R, Peto R, Wheatley K.et al Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994309901–911. - PMC - PubMed
    1. Peto R, Darby S, Deo H.et al Smoking, smoking cessation, and lung cancer ins the UK since 1950: combination of national statistics with two case‐control studies. BMJ 2000321323–329. - PMC - PubMed
    1. Silagy C, Mant D, Fowler G.et al Nicotine replacement therapy for smoking cessation (Cochrane Review, May 1998). In: The Cochrane Library. Oxford: Update software, 2002. (4) - PubMed

MeSH terms